Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases.
Introduction
Infections due to MDR and XDR Gram-negative bacteria have become a global public health problem. 1, 2 Owing to the lack of new antimicrobial agents, treatment has mainly focused on older antibiotics, primarily polymyxins and secondarily fosfomycin. 3 Neither colistin nor fosfomycin has received marketing approval in the modern era.
Several new antibiotics are under development for MDR and XDR Gram-negative bacteria. 4 Among them, cefiderocol (S-649266) appears to have higher activity against MDR bacteria compared with older or upcoming antibiotics. 4 Cefiderocol is actively transported into the periplasmic space along with ferric iron, 5 binds mainly to PBP3 of Gram-negative bacteria and inhibits bacterial cell wall synthesis. 6 Cefiderocol is broadly stable to ESBLs and class A, B, C and D carbapenemases. 5, 7 Published studies on the activity of cefiderocol against Gramnegative bacteria have not focused exclusively on carbapenemresistant bacteria. 5, 8 We sought to investigate the in vitro antimicrobial activity of cefiderocol and that of commercially available comparator antibiotics against a collection of contemporary, clinical, carbapenem-resistant Gram-negative bacteria from inpatients from various Greek hospitals.
Materials and methods

Ethics
The study was approved by the scientific board/ethics committee of Iaso Hospital.
Isolates
Non-duplicate carbapenem-resistant Gram-negative bacteria were collected from the microbiology departments of 18 Greek hospitals. Each hospital provided the available bacteria isolated over the last 7 years (2010-16 
MIC testing
Frozen broth microdilution plates prepared by International Health Management Associates (IHMA; Schaumburg, IL, USA) were used to determine the MICs of cefiderocol and comparators (meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline). Cefiderocol was tested in iron-depleted CAMHB (ID-CAMHB), whereas comparators were tested in CAMHB according to current CLSI guidelines for broth microdilution testing and previously published methodology. 9, 10 Plates with wells containing different concentrations of antibiotics and positive (ID-CAMHB and CAMHB) and negative control wells were stored at -70 C and thawed for 1 h before use. Plates were inoculated with a standardized suspension containing the bacterium under study and sealed. The plates were incubated for 16-20 h at 35 C in a non-CO 2 incubator. If strong growth was confirmed in both growth control wells, reading of the MICs could proceed. Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 and Klebsiella pneumoniae ATCC 700603 were the quality control strains used for each laboratory testing day. If the results for the ATCC quality control strains were outside the expected range recommended by the CLSI, the MIC test was repeated.
The breakpoints for meropenem, ceftazidime, cefepime, aztreonam, amikacin and ciprofloxacin for all species were defined according to the CLSI (NB -the CLSI does not provide breakpoints for aztreonam for Acinetobacter baumannii). Table 1 shows the summary data of the MIC range, MIC 50 and MIC 90 of the antibiotics for the tested bacterial isolates and their respective resistance percentages. The MIC range, MIC 50 and MIC 90 of cefiderocol for meropenem-resistant (,0.03-4, 0.5 and 1, respectively) and meropenem-intermediate (,0.03-1, 0.12 and 0.5 mg/L, respectively) isolates were slightly different. For all 471 isolates tested, regardless of species, cefiderocol had the lowest MIC 90 values among the 11 antibiotics. The highest MIC value of cefiderocol was 4 mg/L, seen in six isolates (five K. pneumoniae and one E. cloacae). These six isolates were all resistant to meropenem, five were resistant to amikacin and ciprofloxacin (the susceptible strain was E. cloacae), one to colistin (K. pneumoniae) and none to tigecycline. The MIC range of ceftolozane/tazobactam and ceftazidime/avibactam was 32 to .64 mg/L and 1 to .64 mg/L, respectively. The cefiderocol MICs for seven E. coli isolates ranged between 0.12 and 1 mg/L and those for four P. mirabilis ranged between 0.06 and 0.5 mg/L. The single S. marcescens had a cefiderocol MIC of 0.25 mg/L and that for K. oxytoca was 0.5 mg/L. 
Discussion
Cefiderocol had lower MICs than any of the 10 comparator antibiotics against a collection of contemporary, clinical, carbapenemnon-susceptible Gram-negative bacterial isolates. Cefiderocol showed potent antimicrobial activity with MIC 90 values 1 mg/L for all groups of organisms. The MIC 90 of cefiderocol was lower for non-fermenting Gram-negative bacteria than for Enterobacteriaceae. Minor differences in MIC values were seen according to specific resistance phenotypes.
Overall, it seems that production of carbapenemases or other broad-spectrum b-lactamases is not a significant source of resistance to cefiderocol. The catalytic efficiency of VIM-2 carbapenemases for cefiderocol was very low in a recent study, while that of KPC carbapenemases could not be determined due to minimal hydrolysis. 7 Another study showed that NDM-1-producing strains (especially E. coli) had higher MICs of cefiderocol. 5 The reason for these elevated MICs for some strains is not clear, but the deficiency of iron-transport systems in P. aeruginosa strains implicated in other siderophore b-lactams is a possible consideration. 13 However, when these same strains of P. aeruginosa were tested under similar experimental conditions, cefiderocol did not demonstrate any discrepancy between in vitro activity and in vivo efficacy as the siderophore monobactams did. 14 A few isolates with higher maximum MIC values (.32 mg/L for A. baumannii, up to 8 mg/L for P. aeruginosa and .64 mg/L for Enterobacteriaceae) have been reported in other studies. 5, 8 Nevertheless, the MIC 90 s of cefiderocol for all species were low and Cefiderocol against carbapenem-resistant Gram-negative bacteria similar to those observed in this study. A different method for preparing iron-depleted media was utilized in these publications and therefore the studies are not directly comparable. This study used the currently approved method with ID-CAMHB. 9 In this collection of carbapenem-resistant isolates, resistance to colistin and amikacin was 32.7% and 54.8%, respectively. The second most active antibiotic was tigecycline. However, tigecycline's clinical utility is limited by several factors. First, it is not active against P. aeruginosa and its activity against A. baumannii is variable. 15 Second, tigecycline is approved for community-acquired pneumonia, intra-abdominal infections and skin infections only. Tigecycline may not be the best option for treatment of patients with bacteraemia, hospital-or ventilator-associated pneumonia and urinary tract infections (UTIs) that constitute the majority of nosocomial infections. 16 Finally, the approved dosing recommendations for infections due to susceptible bacteria may not be adequate to treat MDR/XDR bacteria. 17 Cefiderocol is currently in late-stage clinical development for complicated UTIs and carbapenem-resistant infections (NCT02321800 and NCT02714595). Based on Phase 1 pharmacokinetic exposures and Monte Carlo simulations, cefiderocol has a 90% probability of achieving fT .MIC of 75% for an organism with an MIC of 4 mg/L, which was the highest MIC observed in this study. 18 Although the administration of piperacillin/tazobactam and carbapenems was associated with lower mortality, 19 cephalosporins did not consistently demonstrate better clinical outcomes when administered as prolonged infusions, but their in vivo efficacy is determined by the T .MIC principle as with other b-lactams. 20 In conclusion, cefiderocol exhibited potent antimicrobial activity in vitro against carbapenem-resistant Gram-negative bacteria, including colistin-and aminoglycoside-resistant strains. This activity did not seem to be significantly affected by specific resistance phenotypes. Thus, cefiderocol could be considered as a promising A. baumannii 0.06 (n"100) 0.5 (n"100) 0.06 (n"7) 0.25 (n"7) K. pneumoniae 1 (n"94) 2 (n"94) 0.5 (n"150) 1 (n"150) P. aeruginosa 0.12 (n"49) 0.5 (n"49) 0.06 (n"33) 0.25 (n"33)
JAC
Cefiderocol against carbapenem-resistant Gram-negative bacteria JAC candidate for the treatment of patients with infections due to carbapenem-resistant Gram-negative bacteria.
